Similarly, 72 h of GLP-1 infusion was associated with improved LV ejection fraction in survivors of acute myocardial infarction [26] and GLP-1 analogue (exenatide) administered during percutaneous coronary intervention reduced reperfusion injury and infarct size [31]. The gene discussed is GLP1R; the disease is myocardial infarction.